Layoffs hit another biotech as Duchenne player Solid Bio cuts staff by 35%

Max Gelman

Senior Editor

Another biotech has joined the ranks of the reorganized, as Duchenne player Solid Biosciences reported a new way of doing things Wednesday and announced layoffs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Layoffs hit another biotech as Duchenne player Solid Bio cuts staff by 35%

Max Gelman

Senior Editor

Sign up to read this article for free.

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

J&J's Darzalex hits primary endpoint in Phase 3 early-stage multiple myeloma trial

Vertex makes money from sickle cell therapy Casgevy

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Lay­offs hit an­oth­er biotech as Duchenne play­er Sol­id Bio cuts staff by 35%

Max Gelman

Senior Editor

Sign up to read this article for free.

Zealand’s ‘as­pi­ra­tional’ mis­sion for its amylin drug to be first-line in obe­si­ty

Viking CEO on ‘shock­ing’ mar­ket re­ac­tion to oral obe­si­ty da­ta, prepar­ing for Phase 3

Beam dis­clos­es first clin­i­cal da­ta on base-edit­ed sick­le cell ther­a­py, one pa­tient death

J&J's Darza­lex hits pri­ma­ry end­point in Phase 3 ear­ly-stage mul­ti­ple myelo­ma tri­al

Ver­tex makes mon­ey from sick­le cell ther­a­py Cas­gevy

Gene ther­a­pies don’t have to cost $4 mil­lion: New pro­duc­tion plat­forms re­duce de­vel­op­ment costs and risks

Layoffs hit another biotech as Duchenne player Solid Bio cuts staff by 35%

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

J&J's Darzalex hits primary endpoint in Phase 3 early-stage multiple myeloma trial

Vertex makes money from sickle cell therapy Casgevy

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks